Alexander Vos, VectorY CEO

Start­ing fresh in man­u­fac­tur­ing, For­bion start­up re­fu­els to steer next-gen gene ther­a­py ap­proach for ALS, Alzheimer's in­to clin­ic

For­bion laid out its case for a next-gen­er­a­tion gene ther­a­py ap­proach when it took the wraps off Vec­to­rY Ther­a­peu­tics and its vec­tor­ized an­ti­body tech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.